Guggenheim Downgrades Black Diamond Therapeutics on Silevertinib Concerns

Guggenheim lowers Black Diamond Therapeutics to Neutral, citing toxicity and durability concerns in silevertinib’s Phase 2 trial and risks to key 2026 catalysts.